comprehensive -WSS

comprehensive

author：hotspot 2025-09-11 06:21:26 - browse：3763

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Medtronic CEO on promising devices for diabetes, hypertension

leisure time

WSS

Readout Newsletter: New research from Sanofi, Regeneron, etc.

WHO may add ‘noma' to its list of neglected tropical diseases

Senate panel to vote on hospitals, PBMs, prisoner care

CDC recommends rationing of RSV shot due to shortages

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

Synthetic human embryos? Researchers say term is overblown

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Walensky prepares to leave CDC — and Congress — behind

Emergency medicine has repudiated 'excited delirium.' Now what?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

UnitedHealth wins $3.3 billion takeover of Amedisys

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

First Opinion Podcast: How to protect health care in times of war

Supreme Court strikes down use of affirmative action

Why do we get seasonal allergies?

ChatGPT in medicine: STAT answers readers' burning questions

Brazil's Jair Bolsonaro is barred from running for office until 2030

focus

Why Sanofi got shellacked over its spinoff

Paying for Covid pills will soon shift to insurers

Physician subsidies by hospitals soar in wake of No Surprises Act

Emergency medicine has repudiated 'excited delirium.' Now what?

Here's how to stay safe from wildfire smoke amid reduced air quality

Supreme Court strikes down Biden student loan forgiveness program

leisure time

leisure time

hotspot

Wikipedia